H. Komatani

发表

Expression ratio of CCND1 to CDKN2A mRNA predicts RB1 status of cultured cancer cell lines and clinical tumor samples

T. Machida, H. Kotani, S. Mizuarai, 2011, Molecular Cancer.

Plk3 phosphorylates topoisomerase IIα at Thr1342, a site that is not recognized by Plk1

H. Komatani, M. Matsuda, M. Iida, 2008 .

Plk 3 phosphorylates topoisomerase II α at Thr 1342 , a site that is not recognized by Plk 1

H. Komatani, M. Matsuda, M. Iida, 2008 .

Complete Nucleotide Sequence of the Genomic RNA of Tobacco Mosaic Virus Strain Cg

S. Naito, M. Ishikawa, T. Meshi, 1998, Virus Genes.

Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.

T. Machida, K. Haze, Y. Nakatsuru, 2009, Bioorganic & medicinal chemistry letters.

Overexpression of Plk3 causes morphological change and cell growth suppression in Ras pathway-activated cells.

Takanori Sasaki, H. Komatani, M. Iida, 2009, Journal of biochemistry.

Multiplexed random peptide library and phospho-specific antibodies facilitate human polo-like kinase 1 inhibitor screen.

Erica M. Stec, K. Fukasawa, P. Hodder, 2010, Assay and drug development technologies.

Identification of β-catenin as a novel substrate of polo-like kinase 1

T. Machida, T. Arai, K. Haze, 2008 .

[Novel anti-cancer compounds targeting the cell cycle].

H. Hirai, T. Shimomura, H. Kotani, 2009, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

ABCG2 confers resistance to indolocarbazole compounds by ATP-dependent transport.

S. Nishimura, H. Komatani, Rinako Nakagawa, 2002, Biochemical and biophysical research communications.

Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.

H. Kotani, S. Nishimura, H. Komatani, 2001, Cancer research.

A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.

K. Fukasawa, S. Nishimura, H. Komatani, 1999, Cancer research.

Sequence‐selective DNA cleavage by a topoisomerase I poison, NB‐506

K. Fukasawa, S. Nishimura, H. Komatani, 1998, International journal of cancer.

Structures of the PKC-iota kinase domain in its ATP-bound and apo forms reveal defined structures of residues 533-551 in the C-terminal tail and their roles in ATP binding.

Takashi Yoshizumi, K. Fukasawa, H. Kotani, 2010, Acta crystallographica. Section D, Biological crystallography.

Identification of beta-catenin as a novel substrate of Polo-like kinase 1.

T. Machida, T. Arai, K. Haze, 2008, Cell cycle.

Plk3 phosphorylates topoisomerase IIalpha at Thr(1342), a site that is not recognized by Plk1.

H. Komatani, M. Matsuda, M. Iida, 2008, The Biochemical journal.